Copyright © 2012 Jaclyn L. Kovach et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. J. Z. Nowak, “Age-related macular degeneration (AMD): pathogenesis and therapy,” Pharmacological Reports, vol. 58, no. 3, pp. 353–363, 2006. View at Scopus
2. N. Ferrara, “Vascular endothelial growth factor: basic science and clinical progress,” Endocrine Reviews, vol. 25, no. 4, pp. 581–611, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
3. S. B. Bressler, “Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration,” Ophthalmology, vol. 116, no. 10, pp. S1–S7, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
4. M. G. Krzystolik, M. A. Afshari, A. P. Adamis et al., “Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment,” Archives of Ophthalmology, vol. 120, no. 3, pp. 338–346, 2002. View at Scopus
5. D. Husain, I. Kim, D. Gauthier et al., “Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey,” Archives of Ophthalmology, vol. 123, no. 4, pp. 509–516, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
6. E. S. Gragoudas, A. P. Adamis, E. T. Cunningham, M. Feinsod, and D. R. Guyer, “Pegaptanib for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 351, no. 27, pp. 2805–2816, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
7. VISION Clinical Trial Group, “Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration,” Ophthalmology, vol. 113, pp. 1508–1521, 2006.
8. R. Steinbrook, “The price of sight—ranibizumab, bevacizumab, and the treatment of macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1409–1412, 2006. View at Publisher · View at Google Scholar · View at PubMed
9. S. Sharma and P. K. Kaiser, “Update on VEGF Trap-Eye clinical trials,” Retinal Physician, November 2010.
10. N. Ferrara, K. J. Hillan, H. P. Gerber, and W. Novotny, “Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer,” Nature Reviews Drug Discovery, vol. 3, no. 5, pp. 391–400, 2004.
11. M. J. Tolentino, D. Husain, P. Theodosiadis et al., “Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization,” Archives of Ophthalmology, vol. 118, no. 1, pp. 78–84, 2000.
12. A. A. Moshfeghi, P. J. Rosenfeld, C. A. Puliafito et al., “Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. twenty-four-week results of an uncontrolled open-label clinical study,” Ophthalmology, vol. 113, no. 11, pp. 2002–2011, 2006. View at Publisher · View at Google Scholar · View at PubMed
13. P. J. Rosenfeld, A. A. Moshfeghi, and C. A. Puliafito, “Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration,” Ophthalmic Surgery Lasers and Imaging, vol. 36, no. 4, pp. 331–335, 2005.
14. R. L. Avery, D. J. Pieramici, M. D. Rabena, A. A. Castellarin, M. A. Nasir, and M. J. Giust, “Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration,” Ophthalmology, vol. 114, no. 2, pp. 363–400, 2006. View at Publisher · View at Google Scholar · View at PubMed
15. N. Ferrara, L. Damico, N. Shams, H. Lowman, and R. Kim, “Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration,” Retina, vol. 26, no. 8, pp. 859–870, 2006. View at Publisher · View at Google Scholar · View at PubMed
16. M. W. Stewart, “Predicted biologic activity of intravitreal bevacizumab,” Retina, vol. 27, no. 9, pp. 1196–1200, 2007. View at Publisher · View at Google Scholar · View at PubMed
17. S. J. Bakri, M. R. Snyder, J. M. Reid, J. S. Pulido, M. K. Ezzat, and R. J. Singh, “Pharmacokinetics of intravitreal ranibizumab,” Ophthalmology, vol. 114, no. 12, pp. 2179–2182, 2007. View at Publisher · View at Google Scholar · View at PubMed
18. Pegaptanib Product Information.
19. J. Gaudreault, D. Fei, J. Rusit, P. Suboc, and V. Shiu, “Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration,” Investigative Ophthalmology and Visual Science, vol. 46, no. 2, pp. 726–733, 2005. View at Publisher · View at Google Scholar · View at PubMed
20. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at PubMed
21. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1432–1444, 2006. View at Publisher · View at Google Scholar · View at PubMed
22. P. Abraham, H. Yue, and L. Wilson, “Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2,” American Journal of Ophthalmology, vol. 150, no. 3, pp. 315–324, 2010. View at Publisher · View at Google Scholar · View at PubMed
23. U. Schmidt-Erfurth, B. Eldem, R. Guymer et al., “Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration. the EXCITE study,” Ophthalmology, vol. 118, pp. 831–839, 2010. View at Publisher · View at Google Scholar · View at PubMed
24. G. A. Lalwani, P. J. Rosenfeld, A. E. Fung et al., “A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study,” American Journal of Ophthalmology, vol. 148, no. 1, pp. 1–3, 2009. View at Publisher · View at Google Scholar · View at PubMed
25. D. S. Boyer, J. S. Heier, D. M. Brown, S. F. Francom, T. Ianchulev, and R. G. Rubio, “A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration,” Ophthalmology, vol. 116, no. 9, pp. 1731–1739, 2009. View at Publisher · View at Google Scholar · View at PubMed
26. P. Mitchell, J. F. Korobelnik, P. Lanzetta et al., “Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials,” British Journal of Ophthalmology, vol. 94, no. 1, pp. 2–13, 2010. View at Publisher · View at Google Scholar · View at PubMed
27. “Ranibizumab safe and effective over long term in HORIZON extension study,” Ophthalmology Times, 2009.
28. M. Engelbert, S. A. Zweifel, and K. B. Freund, “"treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation,” Retina, vol. 29, no. 10, pp. 1424–1431, 2009. View at Publisher · View at Google Scholar · View at PubMed
29. H. Oubraham, S. Y. Cohen, S. Samimi et al., “Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration,” Retina, vol. 31, no. 1, pp. 26–30, 2010. View at Publisher · View at Google Scholar · View at PubMed
30. O. P. Gupta, G. Shienbaum, A. H. Patel, C. Fecarotta, R. S. Kaiser, and C. D. Regillo, “A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact,” Ophthalmology, vol. 117, no. 11, pp. 2134–2140, 2010. View at Publisher · View at Google Scholar · View at PubMed
31. A. Tufail, P. J. Patel, C. Egan et al., “Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study,” British Medical Journal, vol. 340, no. 7761, Article ID c2459, p. 1398, 2010. View at Publisher · View at Google Scholar
32. K. C. S. Fong, N. Kirkpatrick, Q. Mohamed, and R. L. Johnston, “Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment,” Clinical and Experimental Ophthalmology, vol. 36, no. 8, pp. 748–755, 2008. View at Publisher · View at Google Scholar · View at PubMed
33. P. J. Mekjavic, A. Kraut, and M. Urbancic, “Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections,” Acta Ophthalmologica, vol. 89, no. 7, pp. 647–653, 2009.
34. C. Leydolt, S. Michels, F. Prager et al., “Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results,” Acta Ophthalmologica, vol. 88, no. 5, pp. 594–600, 2010. View at Publisher · View at Google Scholar · View at PubMed
35. S. T. Luu, T. Gray, S. K. Warrier et al., “Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular age-related macular degeneration in an Australian population,” Clinical and Experimental Ophthalmology, vol. 38, no. 7, pp. 659–663, 2010. View at Publisher · View at Google Scholar · View at PubMed
36. J. F. Arevalo, J. G. Snchez, L. Wu et al., “Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the pan-american collaborative retina study,” Ophthalmology, vol. 117, no. 10, pp. 1974–1981, 2010. View at Publisher · View at Google Scholar · View at PubMed
37. Z. F. Bashshur, Z. A. Haddad, A. R. Schakal, R. F. Jaafar, A. Saad, and B. N. Noureddin, “Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study,” American Journal of Ophthalmology, vol. 148, no. 1, pp. 59–65, 2009. View at Publisher · View at Google Scholar · View at PubMed
38. “Treat-and-extend therapy a popular, cost-effective approach to treating neovascular AMD,” PCONSuperSite, 2011.
39. D. F. Martin, M. G. Maguire, G. -S. Ying, J. E. Grunwald, S. L. Fine, and G. J. Jaffe, “Ranibizumab and bevacizumab for neovascular age-related macular degeneration,” New England Journal of Medicine, vol. 364, no. 20, pp. 1897–1908, 2011. View at Publisher · View at Google Scholar · View at PubMed
40. P. J. Rosenfeld, “Bevacizumab versus ranibizumab—the verdict,” New England Journal of Medicine, vol. 364, no. 20, pp. 1966–1967, 2011. View at Publisher · View at Google Scholar · View at PubMed
41. J. S. Slakter, “What to do when anti-VEGF therapy fails,” Retinal Physician, 2010.
42. A. Y. Lee, A. K. Raya, S. M. Kymes, A. Shiels, and M. A. Brantley, “Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab,” British Journal of Ophthalmology, vol. 93, no. 5, pp. 610–613, 2009. View at Publisher · View at Google Scholar · View at PubMed
43. M. A. Brantley, A. M. Fang, J. M. King, A. Tewari, S. M. Kymes, and A. Shiels, “Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab,” Ophthalmology, vol. 114, no. 12, pp. 2168–2173, 2007. View at Publisher · View at Google Scholar · View at PubMed
44. Q. D. Nguyen, J. Heier, D. Brown, et al., “Randomized, double-masked, active-controlled phase 3 trial of the efficacy and safety of intravitreal VEGF-Trap-Eye in wet AMD: one-year results of the VIEW-1 study,” in Proceedings of the Association for Research in Vision and Ophthalmology, no. 3073, Fort Lauderdale, Fla, USA, 2011.
45. U. Schmidt-Erfurth, V. Chong, B. Kirchhof, et al., “Primary results of an international phase III study using intravitreal VEGF Trap-Eye compared to ranibizumab in patients with wet AMD (VIEW 2),” in Proceedings of the Association for Research in Vision and Ophthalmology, no. 1650, Fort Lauderdale, Fla, USA, 2011.